Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis

Background: Most phase 3 clinical trials of systemic therapy for first-line unresectable hepatocellular carcinoma (HCC) have failed, with the exception of SHARP, REFLECT, and IMbrave150. We conducted indirect comparisons of therapies evaluated for first-line HCC treatment. Summary: We conducted a sy...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Arndt Vogel, Lorenza Rimassa, Hui-Chan Sun, Ghassan K. Abou-Alfa, Anthony El-Khoueiry, David J. Pinato, Javier Sanchez Alvarez, Monica Daigl, Panos Orfanos, Michael Leibfried, Marie-Hélène Blanchet Zumofen, Vincent E. Gaillard, Philippe Merle
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Karger Publishers 2021-05-01
Colecção:	Liver Cancer
Assuntos:	hepatocellular carcinoma cancer immunotherapy atezolizumab meta-analysis
Acesso em linha:	https://www.karger.com/Article/FullText/515302
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!